Display options
Share it on

Intervirology. 2021 Sep 28; doi: 10.1159/000519848. Epub 2021 Sep 28.

Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.

Intervirology

Edwige T Yelemkoure, Albert T Yonli, Hermann K Sombie, Issoufou Tao, Abdou Azaque Zouré, Abdoul Karim Ouattara, Abel P Sorgho, Arsène W Zongo, Moctar T A Zeba, Isabelle T Kiendrebeogo, Prosper Bado, Madeleine K Kabré, Théodora M Zohoncon, Florencia W Djigma, Dorcas Obiri-Yeboah, Jacques Simpore

Affiliations

  1. Laboratory of Molecular Biology and Genetics (LABIOGENE), University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
  2. Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso.
  3. Institute of Sciences, Ouagadougou, Burkina Faso.
  4. Department of Biomedical and Public Heath, Institute for Research in Health Sciences (IRSS/CNRST), Ouagadougou, Burkina Faso.
  5. University Center of Manga, Norbert ZONGO University, Koudougou, Burkina Faso.
  6. University Saint Thomas d'Aquin, Faculty of Medicine, Ouagadougou, Burkina Faso.
  7. Department of Microbiology and Immunology, University of Cape Coast, School of Medical Sciences, Cape Coast, Ghana.

PMID: 34583364 DOI: 10.1159/000519848

Abstract

INTRODUCTION: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV seroprevalence, characterize circulating genotypes, and monitor HCV viral loads in patients under treatment with antivirals.

METHODS: A total of 4,124 individuals and 167 patients in the pre-therapy program were recruited. The "SD Bioline HCV" kit was used for rapid screening of anti-HCV antibodies. Viral load and genotyping were performed in 167 HCV patients on antivirals using the "Iontek HCV Quant" and "Iontek genotyping" kits.

RESULTS: Prevalence of HCV was 1.65% (68/4,124), and the median viral load of participants was 5.37 log10/mL (1.32-7.67 log10/mL). Genotype 2 was predominant with a frequency of 86.23% (144/167) and appeared to be more active with higher viral load compared to 13.77% (23/167) for genotype 1 (p < 0.001). After 24 weeks of pan-genotypic direct-acting antivirals, such as sofosbuvir/daclatasvir and sofosbuvir/velpatasvir, the viral loads of all patients became undetectable.

CONCLUSION: The responses to antivirals by the circulating genotypes indicate that the results are very satisfactory. Therefore, the prevalence of HCV in the population can be reduced through identification of cases and treatment.

© 2021 The Author(s). Published by S. Karger AG, Basel.

Keywords: Burkina Faso; Genotype; Hepatitis C virus; Pan-genotypic drugs; Viral load

Publication Types